Here is the design of a clinical trial:

Official Title: A Digitally Supported Guided Self-determination Intervention Versus Attention Control for People With Type 2 Diabetes in Outpatient Clinics - a Randomised Clinical Trial

Included conditions:
- Type 2 Diabetes

Study Armgroups:
- {'label': 'Guided self-determination', 'type': 'EXPERIMENTAL', 'description': '3 to 5 one-hour digital or analogue guided self-determination sessions', 'interventionNames': ['Behavioral: Guided self-determination']}
- {'label': 'Personal support in goal-pursuing', 'type': 'ACTIVE_COMPARATOR', 'description': 'Up to five personal goal pursuing support sessions', 'interventionNames': ['Behavioral: Personal support in goal-pursuing']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'Guided self-determination', 'description': "Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'....\n\nThe goal is registered.\n\nPatients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2.\n\nA relative may take part in one session completing an analogue reflection sheet as preparation.\n\nParticipants continue usual care.", 'armGroupLabels': ['Guided self-determination']}
- {'type': 'BEHAVIORAL', 'name': 'Personal support in goal-pursuing', 'description': "Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'....\n\nThe goal is registered.\n\nPatients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session.\n\nParticipants continue usual care.", 'armGroupLabels': ['Personal support in goal-pursuing']}

Primary Outcomes:
- {'measure': 'diabetes distress', 'description': 'Assessed by the validated 20-item scale of diabetes-related distress burden, Problem Areas in Diabetes (PAID)', 'timeFrame': 'The Problem area in diabetes (PAID) will be measured at 12-months follow-up. A higher score on the scale (0-100) indicate higher diabetes distress'}

Please estimate the sample size based on the assumption: 
Estimated mean and SD from trials, SD of 16, power of 80% (beta at 20%), significance level (alpha) at 5%, two-tailed.
Sample size
        The sample size was determined by a predicted difference in the primary outcome measure, PAID, between the experimental and control group. We could not identify any previous studies quantising the minimal important difference of PAID. Informed by the estimated mean and SD from the trials included in our systematic review25 (results not yet published), we pragmatically chose six PAID points as the minimal important difference. It must be noted that the minimal important difference should preferably be based on low risk of bias trials, as high risk of bias trials may overestimate the effect.26 Unfortunately, it was only possible to identify trials at high risk of bias in our systematic review.25 In another review conducted by our research group,22 we did, however, identify trials at low risk of bias investigating the effect of psychosocial interventions (not GSD). We found that estimates from these trials at low risk of bias47 roughly corresponded to the minimal important difference and SDs chosen for our sample size calculation. Consistent with these trials that used PAID as an outcome measure, we expect a SD of 16. With a power of 80% (a beta at 20%) and an Î± at 5%, two-tailed, a sample size of 112 participants is needed in each intervention group corresponding to a total of 224 participants included in the trial.